통증 관리 시장

Pain Management Therapeutics Market- Scope of Report

TMR's report on the global Pain Management Therapeutics Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Pain Management Therapeutics Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Pain Management Therapeutics Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Pain Management Therapeutics Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Pain Management Therapeutics Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Pain Management Therapeutics Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Pain Management Therapeutics Market .

The report delves into the competitive landscape of the global Pain Management Therapeutics Market . Key players operating in the global Pain Management Therapeutics Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Pain Management Therapeutics Marketprofiled in this report.

Key Questions Answered in Global Pain Management Therapeutics MarketReport:

• What are the opportunities in the global Pain Management Therapeutics Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Pain Management Therapeutics Market- Research Objectives and Research Approach

The comprehensive report on the global Pain Management Therapeutics Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Pain Management Therapeutics Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Pain Management Therapeutics Market .

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Pain Management Therapeutics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Pain Management Therapeutics Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Regulatory Landscape across Key Regions/Countries
• 5.2. Market Trends
• 5.3. PORTER's Five Forces Analysis
• 5.4. PESTEL Analysis
• 5.5. Key Purchase Metrics for End-users
• 5.6. Brand and Pricing Analysis
• 5.7. Pipeline Analysis
• 5.8. Epidemiology of Major Diseases

6. Global Pain Management Therapeutics Market Analysis and Forecasts, By Drug Class

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Drug Class, 2020 to 2035
  • 6.3.1. Anticonvulsants
  • 6.3.2. Antidepressants
  • 6.3.3. Anaesthetics
  • 6.3.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 6.3.5. Opioids
  • 6.3.6. Anti-migraine Agents
  • 6.3.7. Other
• 6.4. Market Attractiveness By Drug Class

7. Global Pain Management Therapeutics Market Analysis and Forecasts, By Drug Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 7.3.1. Over-the-Counter (OTC) Drugs
  • 7.3.2. Prescription Drugs
• 7.4. Market Attractiveness By Drug Type

8. Global Pain Management Therapeutics Market Analysis and Forecasts, By Pain Type

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Pain Type, 2020 to 2035
  • 8.3.1. Acute Pain
  • 8.3.2. Chronic Pain
• 8.4. Market Attractiveness By Pain Type

9. Global Pain Management Therapeutics Market Analysis and Forecasts, By Route of Administration

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Route of Administration, 2020 to 2035
  • 9.3.1. Oral
  • 9.3.2. Parenteral
  • 9.3.3. Topical
  • 9.3.4. Others
• 9.4. Market Attractiveness By Route of Administration

10. Global Pain Management Therapeutics Market Analysis and Forecasts, By Indication

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By Indication, 2020 to 2035
  • 10.3.1. Arthritic Pain
  • 10.3.2. Bone Facture
  • 10.3.3. Cancer Pain
  • 10.3.4. Chronic Back Pain
  • 10.3.5. Fibromyalgia
  • 10.3.6. Migraine
  • 10.3.7. Muscle Sprain/Strain
  • 10.3.8. Neuropathic Pain
  • 10.3.9. Post-Operative Pain
  • 10.3.10. Others
• 10.4. Market Attractiveness By Indication

11. Global Pain Management Therapeutics Market Analysis and Forecasts, By Distribution Channel

• 11.1. Introduction & Definition
• 11.2. Key Findings / Developments
• 11.3. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Retail Pharmacies
  • 11.3.3. Online Pharmacies
• 11.4. Market Attractiveness By Distribution Channel

12. Global Pain Management Therapeutics Market Analysis and Forecasts, By Region

• 12.1. Key Findings
• 12.2. Market Value Forecast By Region
  • 12.2.1. North America
  • 12.2.2. Europe
  • 12.2.3. Asia Pacific
  • 12.2.4. Latin America
  • 12.2.5. Middle East & Africa
• 12.3. Market Attractiveness By Region

13. North America Pain Management Therapeutics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 13.2.1. Anticonvulsants
  • 13.2.2. Antidepressants
  • 13.2.3. Anaesthetics
  • 13.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 13.2.5. Opioids
  • 13.2.6. Anti-migraine Agents
  • 13.2.7. Other
• 13.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 13.3.1. Over-the-Counter (OTC) Drugs
  • 13.3.2. Prescription Drugs
• 13.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 13.4.1. Acute Pain
  • 13.4.2. Chronic Pain
• 13.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 13.5.1. Oral
  • 13.5.2. Parenteral
  • 13.5.3. Topical
  • 13.5.4. Others
• 13.6. Market Value Forecast By Indication, 2020 to 2035
  • 13.6.1. Arthritic Pain
  • 13.6.2. Bone Facture
  • 13.6.3. Cancer Pain
  • 13.6.4. Chronic Back Pain
  • 13.6.5. Fibromyalgia
  • 13.6.6. Migraine
  • 13.6.7. Muscle Sprain/Strain
  • 13.6.8. Neuropathic Pain
  • 13.6.9. Post-Operative Pain
  • 13.6.10. Others
• 13.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 13.7.1. Hospital Pharmacies
  • 13.7.2. Retail Pharmacies
  • 13.7.3. Online Pharmacies
• 13.8. Market Value Forecast By Country, 2020 to 2035
  • 13.8.1. U.S.
  • 13.8.2. Canada
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Drug Class
  • 13.9.2. By Drug Type
  • 13.9.3. By Pain Type
  • 13.9.4. By Route of Administration
  • 13.9.5. By Indication
  • 13.9.6. By Distribution Channel
  • 13.9.7. By Country

14. Europe Pain Management Therapeutics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 14.2.1. Anticonvulsants
  • 14.2.2. Antidepressants
  • 14.2.3. Anaesthetics
  • 14.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 14.2.5. Opioids
  • 14.2.6. Anti-migraine Agents
  • 14.2.7. Other
• 14.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 14.3.1. Over-the-Counter (OTC) Drugs
  • 14.3.2. Prescription Drugs
• 14.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 14.4.1. Acute Pain
  • 14.4.2. Chronic Pain
• 14.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 14.5.1. Oral
  • 14.5.2. Parenteral
  • 14.5.3. Topical
  • 14.5.4. Others
• 14.6. Market Value Forecast By Indication, 2020 to 2035
  • 14.6.1. Arthritic Pain
  • 14.6.2. Bone Facture
  • 14.6.3. Cancer Pain
  • 14.6.4. Chronic Back Pain
  • 14.6.5. Fibromyalgia
  • 14.6.6. Migraine
  • 14.6.7. Muscle Sprain/Strain
  • 14.6.8. Neuropathic Pain
  • 14.6.9. Post-Operative Pain
  • 14.6.10. Others
• 14.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 14.7.1. Hospital Pharmacies
  • 14.7.2. Retail Pharmacies
  • 14.7.3. Online Pharmacies
• 14.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 14.8.1. Germany
  • 14.8.2. U.K.
  • 14.8.3. France
  • 14.8.4. Italy
  • 14.8.5. Spain
  • 14.8.6. Switzerland
  • 14.8.7. The Netherlands
  • 14.8.8. Rest of Europe
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Drug Class
  • 14.9.2. By Drug Type
  • 14.9.3. By Pain Type
  • 14.9.4. By Route of Administration
  • 14.9.5. By Indication
  • 14.9.6. By Distribution Channel
  • 14.9.7. By Country/Sub-region

15. Asia Pacific Pain Management Therapeutics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 15.2.1. Anticonvulsants
  • 15.2.2. Antidepressants
  • 15.2.3. Anaesthetics
  • 15.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 15.2.5. Opioids
  • 15.2.6. Anti-migraine Agents
  • 15.2.7. Other
• 15.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 15.3.1. Over-the-Counter (OTC) Drugs
  • 15.3.2. Prescription Drugs
• 15.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 15.4.1. Acute Pain
  • 15.4.2. Chronic Pain
• 15.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 15.5.1. Oral
  • 15.5.2. Parenteral
  • 15.5.3. Topical
  • 15.5.4. Others
• 15.6. Market Value Forecast By Indication, 2020 to 2035
  • 15.6.1. Arthritic Pain
  • 15.6.2. Bone Facture
  • 15.6.3. Cancer Pain
  • 15.6.4. Chronic Back Pain
  • 15.6.5. Fibromyalgia
  • 15.6.6. Migraine
  • 15.6.7. Muscle Sprain/Strain
  • 15.6.8. Neuropathic Pain
  • 15.6.9. Post-Operative Pain
  • 15.6.10. Others
• 15.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 15.7.1. Hospital Pharmacies
  • 15.7.2. Retail Pharmacies
  • 15.7.3. Online Pharmacies
• 15.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 15.8.1. China
  • 15.8.2. Japan
  • 15.8.3. India
  • 15.8.4. Australia & New Zealand
  • 15.8.5. South Korea
  • 15.8.6. Rest of Asia Pacific
• 15.9. Market Attractiveness Analysis
  • 15.9.1. By Drug Class
  • 15.9.2. By Drug Type
  • 15.9.3. By Pain Type
  • 15.9.4. By Route of Administration
  • 15.9.5. By Indication
  • 15.9.6. By Distribution Channel
  • 15.9.7. By Country/Sub-region

16. Latin America Pain Management Therapeutics Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 16.2.1. Anticonvulsants
  • 16.2.2. Antidepressants
  • 16.2.3. Anaesthetics
  • 16.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 16.2.5. Opioids
  • 16.2.6. Anti-migraine Agents
  • 16.2.7. Other
• 16.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 16.3.1. Over-the-Counter (OTC) Drugs
  • 16.3.2. Prescription Drugs
• 16.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 16.4.1. Acute Pain
  • 16.4.2. Chronic Pain
• 16.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 16.5.1. Oral
  • 16.5.2. Parenteral
  • 16.5.3. Topical
  • 16.5.4. Others
• 16.6. Market Value Forecast By Indication, 2020 to 2035
  • 16.6.1. Arthritic Pain
  • 16.6.2. Bone Facture
  • 16.6.3. Cancer Pain
  • 16.6.4. Chronic Back Pain
  • 16.6.5. Fibromyalgia
  • 16.6.6. Migraine
  • 16.6.7. Muscle Sprain/Strain
  • 16.6.8. Neuropathic Pain
  • 16.6.9. Post-Operative Pain
  • 16.6.10. Others
• 16.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 16.7.1. Hospital Pharmacies
  • 16.7.2. Retail Pharmacies
  • 16.7.3. Online Pharmacies
• 16.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 16.8.1. Brazil
  • 16.8.2. Mexico
  • 16.8.3. Argentina
  • 16.8.4. Rest of Latin America
• 16.9. Market Attractiveness Analysis
  • 16.9.1. By Drug Class
  • 16.9.2. By Drug Type
  • 16.9.3. By Pain Type
  • 16.9.4. By Route of Administration
  • 16.9.5. By Indication
  • 16.9.6. By Distribution Channel
  • 16.9.7. By Country/Sub-region

17. Middle East & Africa Pain Management Therapeutics Market Analysis and Forecast

• 17.1. Introduction
  • 17.1.1. Key Findings
• 17.2. Market Value Forecast By Drug Class, 2020 to 2035
  • 17.2.1. Anticonvulsants
  • 17.2.2. Antidepressants
  • 17.2.3. Anaesthetics
  • 17.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
  • 17.2.5. Opioids
  • 17.2.6. Anti-migraine Agents
  • 17.2.7. Other
• 17.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 17.3.1. Over-the-Counter (OTC) Drugs
  • 17.3.2. Prescription Drugs
• 17.4. Market Value Forecast By Pain Type, 2020 to 2035
  • 17.4.1. Acute Pain
  • 17.4.2. Chronic Pain
• 17.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 17.5.1. Oral
  • 17.5.2. Parenteral
  • 17.5.3. Topical
  • 17.5.4. Others
• 17.6. Market Value Forecast By Indication, 2020 to 2035
  • 17.6.1. Arthritic Pain
  • 17.6.2. Bone Facture
  • 17.6.3. Cancer Pain
  • 17.6.4. Chronic Back Pain
  • 17.6.5. Fibromyalgia
  • 17.6.6. Migraine
  • 17.6.7. Muscle Sprain/Strain
  • 17.6.8. Neuropathic Pain
  • 17.6.9. Post-Operative Pain
  • 17.6.10. Others
• 17.7. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 17.7.1. Hospital Pharmacies
  • 17.7.2. Retail Pharmacies
  • 17.7.3. Online Pharmacies
• 17.8. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 17.8.1. GCC Countries
  • 17.8.2. South Africa
  • 17.8.3. Rest of Middle East & Africa
• 17.9. Market Attractiveness Analysis
  • 17.9.1. By Drug Class
  • 17.9.2. By Drug Type
  • 17.9.3. By Pain Type
  • 17.9.4. By Route of Administration
  • 17.9.5. By Indication
  • 17.9.6. By Distribution Channel
  • 17.9.7. By Country/Sub-region

18. Competition Landscape

• 18.1. Market Player – Competition Matrix (By Tier and Size of companies)
• 18.2. Market Share Analysis By Company (2024)
• 18.3. Company Profiles
  • 18.3.1. Pfizer Inc.
    • 18.3.1.1. Company Overview
    • 18.3.1.2. Financial Overview
    • 18.3.1.3. Product Portfolio
    • 18.3.1.4. Business Strategies
    • 18.3.1.5. Recent Developments
  • 18.3.2. Eli Lilly and Company
    • 18.3.2.1. Company Overview
    • 18.3.2.2. Financial Overview
    • 18.3.2.3. Product Portfolio
    • 18.3.2.4. Business Strategies
    • 18.3.2.5. Recent Developments
  • 18.3.3. GSK plc
    • 18.3.3.1. Company Overview
    • 18.3.3.2. Financial Overview
    • 18.3.3.3. Product Portfolio
    • 18.3.3.4. Business Strategies
    • 18.3.3.5. Recent Developments
  • 18.3.4. Merck & Co., Inc.
    • 18.3.4.1. Company Overview
    • 18.3.4.2. Financial Overview
    • 18.3.4.3. Product Portfolio
    • 18.3.4.4. Business Strategies
    • 18.3.4.5. Recent Developments
  • 18.3.5. Novartis AG
    • 18.3.5.1. Company Overview
    • 18.3.5.2. Financial Overview
    • 18.3.5.3. Product Portfolio
    • 18.3.5.4. Business Strategies
    • 18.3.5.5. Recent Developments
  • 18.3.6. Johnson & Johnson Services, Inc.
    • 18.3.6.1. Company Overview
    • 18.3.6.2. Financial Overview
    • 18.3.6.3. Product Portfolio
    • 18.3.6.4. Business Strategies
    • 18.3.6.5. Recent Developments
  • 18.3.7. Abbott
    • 18.3.7.1. Company Overview
    • 18.3.7.2. Financial Overview
    • 18.3.7.3. Product Portfolio
    • 18.3.7.4. Business Strategies
    • 18.3.7.5. Recent Developments
  • 18.3.8. Teva Pharmaceutical Industries Ltd.
    • 18.3.8.1. Company Overview
    • 18.3.8.2. Financial Overview
    • 18.3.8.3. Product Portfolio
    • 18.3.8.4. Business Strategies
    • 18.3.8.5. Recent Developments
  • 18.3.9. Mallinckrodt Pharmaceuticals
    • 18.3.9.1. Company Overview
    • 18.3.9.2. Financial Overview
    • 18.3.9.3. Product Portfolio
    • 18.3.9.4. Business Strategies
    • 18.3.9.5. Recent Developments
  • 18.3.10. AstraZeneca
    • 18.3.10.1. Company Overview
    • 18.3.10.2. Financial Overview
    • 18.3.10.3. Product Portfolio
    • 18.3.10.4. Business Strategies
    • 18.3.10.5. Recent Developments
  • 18.3.11. Endo, Inc.
    • 18.3.11.1. Company Overview
    • 18.3.11.2. Financial Overview
    • 18.3.11.3. Product Portfolio
    • 18.3.11.4. Business Strategies
    • 18.3.11.5. Recent Developments
  • 18.3.12. Bayer AG
    • 18.3.12.1. Company Overview
    • 18.3.12.2. Financial Overview
    • 18.3.12.3. Product Portfolio
    • 18.3.12.4. Business Strategies
    • 18.3.12.5. Recent Developments
  • 18.3.13. Sanofi
    • 18.3.13.1. Company Overview
    • 18.3.13.2. Financial Overview
    • 18.3.13.3. Product Portfolio
    • 18.3.13.4. Business Strategies
    • 18.3.13.5. Recent Developments
  • 18.3.14. Viatris Inc
    • 18.3.14.1. Company Overview
    • 18.3.14.2. Financial Overview
    • 18.3.14.3. Product Portfolio
    • 18.3.14.4. Business Strategies
    • 18.3.14.5. Recent Developments
  • 18.3.15. Haleon plc
    • 18.3.15.1. Company Overview
    • 18.3.15.2. Financial Overview
    • 18.3.15.3. Product Portfolio
    • 18.3.15.4. Business Strategies
    • 18.3.15.5. Recent Developments
  • 18.3.16. Impax Laboratories, Inc.
    • 18.3.16.1. Company Overview
    • 18.3.16.2. Financial Overview
    • 18.3.16.3. Product Portfolio
    • 18.3.16.4. Business Strategies
    • 18.3.16.5. Recent Developments
  • 18.3.17. Lupin Limited
    • 18.3.17.1. Company Overview
    • 18.3.17.2. Financial Overview
    • 18.3.17.3. Product Portfolio
    • 18.3.17.4. Business Strategies
    • 18.3.17.5. Recent Developments